Research on the treatment of metastatic colon cancer patients treated by FOLFOXIRI: Efficacy and toxicity of first-line treatment in stage IV metastatic colorectal cancer patients

Background: In recent years, the new trend in treatment of colorectal cancer is the use of target drug. We conduct the study to evaluate efficacy of triplet combination chemotherapy of 5-fluorouracil/leucovorin, oxapilatin, and irinotecan (FOLFOXIRI) in the treatment of stage IV colorectal cancer patients. Method: Uncontrolled clinical trial carried on 39 stage IV colorectal cancer patients Results: The overall response rate of the treatment was 75%. Mean of progression free survival was 13.4 ± 9 months. The overall survival rate at 12th month and 24th month were 90% and 76%, respectively. The proportion of granulocytopenia was 48.9%, no grade 3 or 4. Side effect beyond hematology was most seen in hepatic toxicity with 52.5%, mainly at grade 1. Vomiting was 18.3%, all at grade 1. Other toxicity was very low at percentage. Conclusion: The triplet combination FOLFOXIRIN chemotherapy improves the outcome of patient with metal colorectal cancer in term of response rate, overall survival rate and progression free survival, and the level of toxicity was acceptable..